Hepatitis C virus core antigen testing: Role in diagnosis, disease monitoring and treatment

World Journal of Gastroenterology

Volumn 20, Issue 22, 2014, Pages 6701-6706

  Tillmann, Hans L ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

Diagnostic accuracy; Diagnostic assay; Hepatitis C; Hepatitis C virus; Hepatitis C virus core antigen; Treatment monitoring

Indexed keywords

HEPATITIS C ANTIGEN; HEPATITIS C CORE ANTIGEN; PEGINTERFERON; RIBAVIRIN; UNCLASSIFIED DRUG; VIRUS RNA; ANTIVIRUS AGENT; BIOLOGICAL MARKER; CORE PROTEIN; HEPATITIS C ANTIBODY;

ALGORITHM; ANTIGEN TESTING; ANTIVIRAL THERAPY; ARTICLE; BLOOD BANK; CORRELATION ANALYSIS; DIAGNOSTIC ALGORITHM; HEPATITIS C; HISTOLOGY; HUMAN; IMMUNOLOGICAL PROCEDURES; MONITORING; ORGAN DONOR; SENSITIVITY AND SPECIFICITY; VIRAL CLEARANCE; BLOOD; DRUG EFFECTS; DRUG MONITORING; GENETICS; HEPACIVIRUS; IMMUNOLOGY; PREDICTIVE VALUE; PROCEDURES; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; DRUG MONITORING; HEPACIVIRUS; HEPATITIS C; HEPATITIS C ANTIBODIES; HEPATITIS C ANTIGENS; HUMANS; PREDICTIVE VALUE OF TESTS; RNA, VIRAL; TREATMENT OUTCOME; VIRAL CORE PROTEINS;

EID: 84902199516     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i22.6701     Document Type: Article

References (31)

1. Zuckerman AJ. The elusive hepatitis C virus. BMJ 1989; 299: 871-873 [PMID: 2510874]
2. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244: 359-362 [PMID: 2523562]
3. Kuo G, Choo QL, Alter HJ, Gitnick GL, Redeker AG, Purcell RH, Miyamura T, Dienstag JL, Alter MJ, Stevens CE. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 1989; 244: 362-364 [PMID: 2496467]
4. Pradat P, Chossegros P, Bailly F, Pontisso P, Saracco G, Sauleda S, Thursz M, Tillmann H, Vlassopoulou H, Alberti A, Braconier JH, Esteban JI, Hadziyannis S, Manns M, Rizzetto M, Thomas HC, Trépo C. Comparison between three quantitative assays in patients with chronic hepatitis C and their relevance in the prediction of response to therapy. J Viral Hepat 2000; 7: 203-210 [PMID: 10849262]
5. Pas S, Molenkamp R, Schinkel J, Rebers S, Copra C, Seven-Deniz S, Thamke D, de Knegt RJ, Haagmans BL, Schutten M. Performance evaluation of the new Roche cobas AmpliPrep/ cobas TaqMan HCV test, version 2.0, for detection and quantification of hepatitis C virus RNA. J Clin Microbiol 2013; 51: 238-242 [PMID: 23152551 DOI: 10.1128/ JCM.01729-12]
6. Ji W, Kim DS, Jung SW, Yu YD, Suh SO. Pre-emptive therapy for the cytomegalovirus infection after liver transplantation in endemic areas and its optimal diagnostic method. Transplant Proc 2013; 45: 3065-3068 [PMID: 24157037 DOI: 10.1016/j.transproceed.2013.08.042]
7. Marchetti S, Santangelo R, Manzara S, D'onghia S, Fadda G, Cattani P. Comparison of real-time PCR and pp65 antigen assays for monitoring the development of Cytomegalovirus disease in recipients of solid organ and bone marrow transplants. New Microbiol 2011; 34: 157-164 [PMID: 21617827]
8. Drew WL. Laboratory diagnosis of cytomegalovirus infection and disease in immunocompromised patients. Curr Opin Infect Dis 2007; 20: 408-411 [PMID: 17609601]
9. Tedder RS, Tuke P, Wallis N, Wright M, Nicholson L, Grant PR. Therapy-induced clearance of HCV core antigen from plasma predicts an end of treatment viral response. J Viral Hepat 2013; 20: 65-71 [PMID: 23231086 DOI: 10.1111/ j.1365-2893.2012.01630.x]
10. Murayama A, Sugiyama N, Watashi K, Masaki T, Suzuki R, Aizaki H, Mizuochi T, Wakita T, Kato T. Japanese reference panel of blood specimens for evaluation of hepatitis C virus RNA and core antigen quantitative assays. J Clin Microbiol 2012; 50: 1943-1949 [PMID: 22495557 DOI: 10.1128/ JCM.00487-12]
11. Ottiger C, Gygli N, Huber AR. Detection limit of architect hepatitis C core antigen assay in correlation with HCV RNA, and renewed confirmation algorithm for reactive anti-HCV samples. J Clin Virol 2013; 58: 535-540 [PMID: 24041472 DOI: 10.1016/j.jcv.2013.08.028]
12. Ross RS, Viazov S, Salloum S, Hilgard P, Gerken G, Roggendorf M. Analytical performance characteristics and clinical utility of a novel assay for total hepatitis C virus core antigen quantification. J Clin Microbiol 2010; 48: 1161-1168 [PMID: 20107102 DOI: 10.1128/JCM.01640-09]
13. Fytili P, Tiemann C, Wang C, Schulz S, Schaffer S, Manns MP, Wedemeyer H. Frequency of very low HCV viremia detected by a highly sensitive HCV-RNA assay. J Clin Virol 2007; 39: 308-311 [PMID: 17625963]
14. Morota K, Fujinami R, Kinukawa H, Machida T, Ohno K, Saegusa H, Takeda K. A new sensitive and automated chemiluminescent microparticle immunoassay for quantitative determination of hepatitis C virus core antigen. J Virol Methods 2009; 157: 8-14 [PMID: 19135481 DOI: 10.1016/ j.jviromet.2008.12.009]
15. Medici MC, Furlini G, Rodella A, Fuertes A, Monachetti A, Calderaro A, Galli S, Terlenghi L, Olivares M, Bagnarelli P, Costantini A, De Conto F, Sainz M, Galli C, Manca N, Landini MP, Dettori G, Chezzi C. Hepatitis C virus core antigen: analytical performances, correlation with viremia and potential applications of a quantitative, automated immunoassay. J Clin Virol 2011; 51: 264-269 [PMID: 21621454 DOI: 10.1016/j.jcv.2011.05.003]
16. Miedouge M, Saune K, Kamar N, Rieu M, Rostaing L, Izopet J. Analytical evaluation of HCV core antigen and interest for HCV screening in haemodialysis patients. J Clin Virol 2010; 48: 18-21 [PMID: 20233674 DOI: 10.1016/ j.jcv.2010.02.012]
17. Waldenström J, Konar J, Ekermo B, Norder H, Lagging M. Neonatal transfusion-transmitted hepatitis C virus infection following a pre-seroconversion window-phase donation in Sweden. Scand J Infect Dis 2013; 45: 796-799 [PMID: 23746339 DOI: 10.3109/00365548.2013.797601]
18. Mederacke I, Wedemeyer H, Ciesek S, Steinmann E, Raupach R, Wursthorn K, Manns MP, Tillmann HL. Performance and clinical utility of a novel fully automated quantitative HCV-core antigen assay. J Clin Virol 2009; 46: 210-215 [PMID: 19766055 DOI: 10.1016/j.jcv.2009.08.014]
19. Mederacke I, Potthoff A, Meyer-Olson D, Meier M, Raupach R, Manns MP, Wedemeyer H, Tillmann HL. HCV core antigen testing in HIV-and HBV-coinfected patients, and in HCV-infected patients on hemodialysis. J Clin Virol 2012; 53: 110-115 [PMID: 22177274 DOI: 10.1016/j.jcv.2011.11.009]
20. Tillmann HL, Wiegand J, Glomb I, Jelineck A, Picchio G, Wedemeyer H, Manns MP. Diagnostic algorithm for chronic hepatitis C virus infection: role of the new HCV-core antigen assay. Z Gastroenterol 2005; 43: 11-16 [PMID: 15650966]
21. Kuo YH, Chang KC, Wang JH, Tsai PS, Hung SF, Hung CH, Chen CH, Lu SN. Is hepatitis C virus core antigen an adequate marker for community screening? J Clin Microbiol 2012; 50: 1989-1993 [PMID: 22461676 DOI: 10.1128/ JCM.05175-11]
22. Moini M, Ziyaeyan M, Aghaei S, Sagheb MM, Taghavi SA, Moeini M, Jamalidoust M, Hamidpour L. Hepatitis C virus (HCV) Infection Rate among Seronegative Hemodialysis Patients Screened by Two Methods; HCV Core Antigen and Polymerase Chain Reaction. Hepat Mon 2013; 13: e9147 [PMID: 24032048 DOI: 10.5812/hepatmon.9147]
23. Fujino T, Nakamuta M, Aoyagi Y, Fukuizumi K, Takemoto R, Yoshimoto T, Miyahara T, Harada N, Sakai H, Nakashima M, Enjoji M. Early decline of the HCV core antigen can predict SVR in patients with HCV treated by Pegylated interferon plus ribavirin combination therapy. J Dig Dis 2009; 10: 21-25 [PMID: 19236543 DOI: 10.1111/ j.1751-2980.2008.00358.x]
24. Matsui K, Iwabuchi S, Shimizu H, Yoshida A, Fujikawa T, Takatsuka K. Two week induction of interferon-beta followed by pegylated interferon alpha-2b and ribavirin for chronic infection with hepatitis C. Hepatol Res 2010; 40: 757-762 [PMID: 20557368 DOI: 10.1111/j.1872-034X.2010.00669.x]
25. Wada Y, Tamai H, Uno A, Kawashima A, Shingaki N, Mori Y, Moribata K, Miyata K, Higashi K, Deguchi H, Ueda K, Inoue I, Maekita T, Iguchi M, Kato J, Ichinose M. Prediction of efficacy to pegylated interferon-α-2b plus ribavirin in patients with genotype 2 hepatitis C virus using viral response within 2 weeks. Hepatol Res 2014; 44: 179-186 [PMID: 23531032 DOI: 10.1111/hepr.12101]
26. Vermehren J, Susser S, Berger A, Perner D, Peiffer KH, Allwinn R, Zeuzem S, Sarrazin C. Clinical utility of the ARCHITECT HCV Ag assay for early treatment monitoring in patients with chronic hepatitis C genotype 1 infection. J Clin Virol 2012; 55: 17-22 [PMID: 22698697 DOI: 10.1016/ j.jcv.2012.05.008]
27. Loggi E, Cursaro C, Scuteri A, Grandini E, Panno AM, Galli S, Furlini G, Bernardi M, Galli C, Andreone P. Patterns of HCV-RNA and HCV core antigen in the early monitoring of standard treatment for chronic hepatitis C. J Clin Virol 2013; 56: 207-211 [PMID: 23245628 DOI: 10.1016/j.jcv.2012.11.012]
28. Tamai H, Shingaki N, Shiraki T, Tukuda H, Mori Y, Moribata K, Enomoto S, Deguchi H, Ueda K, Inoue I, Maekita T, Iguchi M, Yanaoka K, Oka M, Ichinose M. Prediction of sustained response to low-dose pegylated interferon alpha-2b plus ribavirin in patients with genotype 1b and high hepatitis C virus level using viral reduction within 2 weeks after therapy initiation. Hepatol Res 2011; 41: 1137-1144 [PMID: 21951330 DOI: 10.1111/j.1872-034X.2011.00879.x]
29. Shouval D. Focus: quantitative HBsAg measurement as a new surrogate marker for assessment of hepatic fibrosis in HBeAg+ chronic hepatitis B. J Hepatol 2013; 58: 1063-1064 [PMID: 23499728 DOI: 10.1016/j.jhep.2013.03.002]
30. Durante-Mangoni E, Vallefuoco L, Sorrentino R, Iossa D, Perna E, Molaro R, Braschi U, Zampino R, Sodano G, Adinolfi LE, Utili R, Portella G. Clinico-pathological significance of hepatitis C virus core antigen levels in chronic infection. J Med Virol 2013; 85: 1913-1918 [PMID: 23897630 DOI: 10.1002/jmv.23672]
31. Carabaich A, Ruvoletto M, Bernardinello E, Tono N, Cavalletto L, Chemello L, Gatta A, Pontisso P. Profiles of HCV core protein and viremia in chronic hepatitis C: possible protective role of core antigen in liver damage. J Med Virol 2005; 76: 55-60 [PMID: 15778969]